Association between sleep paralysis and anxiety: a systematic review and meta-analysis.

J Clin Sleep MedSep 10, 2026 (epub)
Clinical ResearchPsychiatryOpen access

Gustavo Garrido, Kenzo Donato, João Victor Gonzalez et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the association between sleep paralysis and anxiety, involving 5568 participants across 11 studies. The analysis found that sleep paralysis was linked to significantly higher anxiety scores (SMD 0.35; 95% CI 0.27-0.44; p < 0.01), indicating a notable relationship between these conditions.

Key findings

  • Sleep paralysis was associated with significantly higher anxiety scores (SMD 0.35; 95% CI 0.27-0.44; p < 0.01).
  • No significant difference in anxiety prevalence was found (RR 1.28; 95% CI 0.59-2.77; p = 0.53).
  • Excluding one outlier showed a significant risk of anxiety prevalence (RR 1.80; 95% CI 1.08-2.99).

Why it matters

Understanding the relationship between sleep paralysis and anxiety can help clinicians recognize potential comorbidities in patients presenting with sleep disturbances, leading to more comprehensive management strategies.

Source

PubMed · PMID 42722931Free full text on PubMed Central

Published in J Clin Sleep Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.